Penserra Capital Management
LRMR icon

Penserra Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Penserra Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-405
Closed -$4K – 1466
2021
Q3 		$4K Buy
405
+55
+16% +$660 ﹤0.01% 1420
2021
Q2 		$3K Hold
350
– – ﹤0.01% 1327
2021
Q1 		$5K Sell
350
-5
-1% -$91 ﹤0.01% 1086
2020
Q4 		$7K Buy
+355
New +$7.11K ﹤0.01% 961

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Penserra Capital Management's LRMR Position: Q4 2021 in Review

Penserra Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2021, closing a stake of 405 shares — an estimated $4K sold.

Penserra Capital Management first reported a position in LRMR in Q4 2020 and held it in 4 quarters. The position peaked at $7K in Q4 2020. 49 funds tracked by Wall St. Rank hold LRMR as of Q4 2021.

  • Penserra Capital Management reported no remaining Larimar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 405 Larimar Therapeutics shares in Q4 2021, an estimated $4K.
  • Penserra Capital Management first reported a position in Larimar Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Larimar Therapeutics position peaked at $7K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.